Corporate Finance
Bergs Securities acted as Sole Manager to Observit in its SEK 26 million directed share issue to Eiffel Investment Group
Bergs Securities acted as joint bookrunner in connection with the SEK 100m rights issue in Nanologica
Corporate Finance
Bergs Securities is proud to have acted as joint bookrunner in connection with the SEK 100m rights issue in Nanologica
Nanologica is a Swedish life science tools company that provides consumables to pharmaceutical manufacturers. Nanologica’s products are specially developed for the purification of peptide drugs, such as insulin and GLP-1 analogues. Due to effective purification and a long lifetime for the products, they can increase productivity and reduce costs for pharmaceutical manufacturers. Nanologica operates in a global niche market that is growing as a result of increased demand for drugs for the treatment of diabetes and obesity. The company’s mission is to increase access to cost-effective drugs through its purification products and thereby contribute to more patients around the world having access to life-saving treatments.
Related News
Corporate Finance
Bergs Securities acted as sole manager and bookrunner to Initiator Pharma Therapeutics in its SEK 56 million rights issue
Corporate Finance
Bergs Securities assisted Smart Eye in the exercise of an incentive program resulting in 497 280 newly issued shares of which around half was divested through a block trade